(NASDAQ: COGT) Cogent Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.18%.
Cogent Biosciences's revenue in 2025 is $0.On average, 4 Wall Street analysts forecast COGT's revenue for 2026 to be $5,165,947,834, with the lowest COGT revenue forecast at $315,364,749, and the highest COGT revenue forecast at $12,956,140,242. On average, 5 Wall Street analysts forecast COGT's revenue for 2027 to be $25,608,983,844, with the lowest COGT revenue forecast at $7,448,072,888, and the highest COGT revenue forecast at $69,494,094,936.
In 2028, COGT is forecast to generate $46,422,374,198 in revenue, with the lowest revenue forecast at $26,151,365,673 and the highest revenue forecast at $66,693,382,722.